ArticleFrontiers in nutrition2026
Association of the cholesterol-high-density lipoprotein-glucose index with coronary atherosclerotic burden in patients with coronary artery disease.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The cholesterol-high-density lipoprotein-glucose (CHG) index is a novel composite metabolic marker, but its association with coronary atherosclerotic burden in patients with coronary artery disease (CAD) remains unclear. This study aimed to investigate the association between the CHG index and the Gensini score in patients with CAD. Methods: We included patients with CAD admitted between January 2024 and January 2025. Multivariable linear regression and restricted cubic spline (RCS) analyses were performed to evaluate the association and dose-response relationship between the CHG index and log-transformed (Gensini score + 1). Subgroup and sensitivity analyses assessed the robustness of the findings. Receiver operating characteristic (ROC) curve analysis was used to evaluate discriminative ability for identifying high coronary atherosclerotic burden. Net reclassification improvement (NRI), integrated discrimination improvement (IDI), and decision curve analysis (DCA) were used to assess the incremental value of the CHG index. Results: A total of 758 participants were included. In the fully adjusted model, each 1-SD increase in the CHG index was associated with a 0.121-unit increase in log-transformed (Gensini score + 1) ( Conclusion: A higher CHG index was associated with a higher Gensini score in patients with CAD. As a simple and inexpensive metabolic marker, the CHG index may provide complementary information for assessing coronary atherosclerotic burden. However, its clinical utility requires further evaluation in prospective studies incorporating external validation and longitudinal clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.